Tesamorelin Peptide Therapy in Alpharetta

What tesamorelin is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). Under the brand name Egrifta, it is FDA approved for one specific purpose: reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat redistribution linked to HIV and its treatment. That is the entire scope of its approval. Any other application — general fat loss, anti-aging, athletic performance, or cognitive enhancement — is off-label and was not the basis for FDA review.

Egrifta was originally approved in 2010, and the FDA has since reviewed reformulations of the same molecule, including a formulation marketed as Egrifta WR. Each of those reviews has stayed within the same approved indication: HIV-associated lipodystrophy. No FDA review of tesamorelin, in any formulation, has extended the approved use to weight management in the general population or to any anti-aging claim.

How it is thought to work

As a GHRH analogue, tesamorelin binds pituitary GHRH receptors and stimulates the release of endogenous growth hormone, which in turn raises circulating insulin-like growth factor-1 (IGF-1). This growth hormone/IGF-1 axis is understood to influence fat metabolism, including a relatively selective effect on visceral fat, the fat stored around abdominal organs, which is the mechanism the approved indication is built on.

The reason tesamorelin was studied specifically in HIV-associated lipodystrophy is that the condition involves a distinctive pattern of fat redistribution, with visceral fat accumulation alongside subcutaneous fat loss, thought to relate to both the virus and certain antiretroviral medications. That specific physiology is part of why the trial population was defined so narrowly, and why the approved indication does not automatically extend to abdominal fat from other causes.

What the research shows

The pivotal evidence is a randomized, double-blind, placebo-controlled trial of 412 adults with HIV who had excess abdominal fat, enrolled across 43 sites. Participants received either daily tesamorelin or placebo for 26 weeks, with an additional 26-week extension to assess long-term safety. Visceral adipose tissue, measured by CT scan, decreased by 15.2% in the tesamorelin group compared with a 5.0% increase in the placebo group, a statistically significant difference (Falutz et al., 2007, New England Journal of Medicine). Subcutaneous fat and limb fat did not show the same reduction, underscoring that the studied effect was relatively specific to visceral fat in this population.

This trial is exactly the kind of evidence the other compounds on this site generally lack: a defined population, a placebo comparator, and a measured outcome. It is still important to state its limits precisely. The population studied was adults with HIV-associated lipodystrophy, not the general population seeking fat loss, and the FDA approval tracks that population exactly.

A related randomized trial of 404 people with HIV and excess abdominal fat extended the observation window, with a 6-month primary treatment phase followed by a 6-month extension in which the placebo group crossed over to tesamorelin, allowing researchers to assess whether the visceral-fat effect persisted with continued use (Falutz et al., PubMed). That trial, too, was conducted exclusively in people with HIV-associated lipodystrophy, and its findings do not extend the evidence base to people outside that population.

What it is not

Tesamorelin is not approved for weight loss in people without HIV-associated lipodystrophy, and it is not an anti-aging therapy, despite frequent marketing to that effect. Using it outside its approved indication is off-label, meaning it falls outside what the pivotal trial and the FDA review actually covered, and outcomes in a different population have not been established with the same rigor. It should not be presented as a substitute for structured metabolic care, including medical weight loss programs built around your own metabolic diagnostics.

It is also not a general growth hormone replacement therapy. Tesamorelin's approval is specific to visceral fat reduction in a defined clinical population, not to broader growth hormone deficiency, and it should not be conflated with prescription growth hormone therapy managed for a diagnosed deficiency.

How Aeon approaches it

We treat tesamorelin's FDA approval as real and worth stating precisely, and we are equally precise about where that approval ends. If HIV-associated lipodystrophy is not your situation, any use of tesamorelin would be off-label, and our clinical team will say so directly in consultation, alongside a review of your clinic lab results and whether an on-label, better-evidenced path serves your goal instead.

We think that honesty is the more useful starting point than a marketing page that quietly drops the word "HIV-associated" and lets the approval sound broader than it is. A consultation is where we lay out the actual boundary, and where an appropriate, on-label alternative can be discussed if one applies to your situation.